68 results about "Subtyping" patented technology

The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.

The invention relates to a circulating tumor cell detection kit and application thereof. The circulating tumor cell detection kit comprises a chip, sample diluent, a cell separation fluid, a cell trapping agent, a cell cleaning solution, a cell fixing agent, antibody diluent, a cell penetration agent and a fluorescence dye. The application method of the circulating tumor cell detection kit mainly comprises the several steps of separation of circulating tumor cells, trapped antibody coating, trapping of the circulating tumor cells and immuno-fluorescent staining of the circulating tumor cells. The circulating tumor cell detection kit is mainly used for tumor prognosis, reappear, metastasis, curative effect monitoring, early diagnosis and early warning, monitoring of curative effect and tumor progression situation, and utilizes the molecular subtyping, screening specificity and other characteristics of the circulating tumor cells to conduct targeted research on circulating tumor cell sensitive drug so as to supplement tumor metastasis, relapse and drug resistance mechanisms and guide individualized medical treatment.

The invention discloses a group of genes for tumor molecular subtyping. The group of genes includes 38 genes such as an ACPP gene and an AGR2 gene. Moreover, the invention further discloses a kit for tumor molecular subtyping and application of the kit. The group of genes is beneficial to the recognition of the tissue sources of tumors. After a tumor sample is obtained, the tissue source and cancer type of the tumor sample can be judged objectively and accurately through detection and conjoint analysis of the gene group, so that a patient can be treated specifically.

The invention relates generally to the field of cancer detection, diagnosis, subtyping, staging, prognosis, treatment and prevention. More particularly, the present invention relates to methods for the detection, and / or diagnosing and / or subtyping and / or staging of lung cancer in a patient. Based on a particular panel of biomarkers, the present invention provides methods to detect, diagnose at an early stage and / or differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) and within NSCLC to differentiate between squamous cell carcinomas (SCC), adenocarcinomas (AC), within SCC to discriminate G2 and G3 stage and within lung cancer to differentiate for lung cancers with or without neuroendocrine origin. It further provides the use of said panel of biomarkers in monitoring disease progression in a patient, including both in vitro and in vivo imaging techniques. The in vitro imaging techniques typically include an immunoassay detecting protein or antibody of the biomarkers on a sample taken from said patient, e.g. serum or tissue sample. The in vivo imaging techniques typically include chest radiographs (X-rays), Computed Tomography (CT) imaging, spiral CT, Positron Emission Tomography (PET), PET-CT and scintigraphy for molecular imaging and diagnosis and to monitor disease progression and treatment response in patients. It is accordingly a further aspect to provide a kit to perform the aforementioned diagnosing and / or subtyping and / or staging assay and the imaging techniques, comprising reagents to determine the gene expression or protein level of the aforementioned panel of biomarkers for in vitro and in vivo applications.

The invention relates generally to the field of cancer detection, diagnosis, subtyping, staging, prognosis, treatment and prevention. More particularly, the present invention relates to methods for the detection, and / or diagnosing and / or subtyping and / or staging of lung cancer in a patient. Based on a particular panel of biomarkers, the present invention provides methods to detect, diagnose at an early stage and / or differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) and within NSCLC to differentiate between squamous cell carcinomas (SCC), adenocarcinomas (AC), within SCC to discriminate G2 and G3 stage and within lung cancer to differentiate for lung cancers with or without neuroendocrine origin. It further provides the use of said panel of biomarkers in monitoring disease progression in a patient, including both in vitro and in vivo imaging techniques. The in vitro imaging techniques typically include an immunoassay detecting protein or antibody of the biomarkers on a sample taken from said patient, e.g. serum or tissue sample. The in vivo imaging techniques typically include chest radiographs (X-rays), Computed Tomography (CT) imaging, spiral CT, Positron Emission Tomography (PET), PET-CT and scintigraphy for molecular imaging and diagnosis and to monitor disease progression and treatment response in patients. It is accordingly a further aspect to provide a kit to perform the aforementioned diagnosing and / or subtyping and / or staging assay and the imaging techniques, comprising reagents to determine the gene expression or protein level of the aforementioned panel of biomarkers for in vitro and in vivo applications.

The invention discloses a small program code compiling method and device, equipment and a medium and relates to the technical field of financial science and technology, the method is applied to the applet code compiler, wherein a main package configuration file is set in the compiler; subpackaging configuration files and processing queues, the applet code compiling method comprises the following steps: compiling applet codes; when a small program code compiling instruction is received; obtaining all file contents corresponding to the main package configuration file and the sub-package configuration file, setting branch codes required by different sub-type small programs in the small programs in the sub-package configuration file, and setting universal codes required by different sub-type small programs in the small programs in the main package configuration file; obtaining a to-be-processed node based on all the file contents; and placing the to-be-processed node in the processing queue to perform queuing compilation processing to obtain a compiled file. The technical problems that in existing applet code compiling, maintainability is poor, and code reusability is poor are solved.

Systems, methods, and structures are discussed that enhance type reconstruction for programs. Whereas previous methods insufficiently provide the set of types necessary for program analysis, the embodiments of the present invention can accept any verifiable bytecode programs and produce a set of types needed for program analysis. The embodiments of the present invention provide a technique called subtype completion that transforms a subtyping system by extending its type hierarchy to a lattice. However, such transformation inserts only a minimal amount of elements so as to enhance the computation of reconstructed types.

In general, the present invention relates to identification of lipidome biomarkers for cancer analysis and it provides prognostic and predictive methods and kits for cancer diagnosis and subtyping and for diagnosing and / or predicting the evolution of a tumor and its response to lipid metabolism-targeted or other types of therapy in a subject, by making use of phospholipid (PL) profiling, wherein changes in the combined acyl chain length of intact body fluid-derived or tumor-derived phospholipid species is indicative of an elongation phenotype.